Both DHA and EPA have been suggested to exert atheroprotective functions by promoting intracellular catabolism of apolipoprotein-B-100–containing lipoproteins, suppressing hepatic apolipoprotein-B production, stimulating plasma TG clearance via lipoprotein lipase, increasing the VLDL to LDL conversion rate, reducing LDL synthesis, and attenuating postprandial lipemia [19,20]. The gene discussed is APOB; the disease is hyperlipidemia.